Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$8.27 USD
+0.10 (1.22%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $8.46 +0.19 (2.30%) 4:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
ATRA 8.27 +0.10(1.22%)
Will ATRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATRA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATRA
All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
ATRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
Other News for ATRA
Biotech Alert: Searches spiking for these stocks today
Atara Biotherapeutics Receives Buy Rating Amidst Positive FDA Review and Solid Financial Outlook
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel?) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Atara announces $20M milestone from Pierre Fabre amid filing of tab-cel BLA
Atara lead asset tab-cel undergoes FDA priority review